Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1401 with Immune Stimulants in NY-ESO-1 Expressing Cancers
NCT00948961Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Sep 2009
- Primary completion
- Jun 2012
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of CDX-1401 in bladder cancer, breast cancer, ovarian cancer and 4 more (3 arms), sponsored by Celldex Therapeutics. Primary endpoint: Occurrence of adverse events at 12 weeks. Started Sep 2009; status: completed.
02
Drugs
CDX-1401
03
Conditions
bladder cancerbreast cancerovarian cancernon-small cell lung cancer (NSCLC)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00948961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948961.